Targeted Protein Degradation Market Size, Share & Industry Analysis, By Degradation Platform (Molecular Glue Degraders, Lysosome-targeted Degraders, PROTACs, Autophagy-targeted Degraders, Antibody-based targeted Degraders, Hydrophobic Tagging–based Degraders, and Others), By Drug (Thalidomide, Lenalidomide, Fulvestrant, Elacestrant, and Others), By Indication (Hematologic Malignancies, Solid Tumors, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2026-2034

The global targeted protein degradation market size was valued at USD 5.95 billion in 2025. The market is projected to grow from USD 5.88 billion in 2026 to USD 12.44 billion by 2034, exhibiting a CAGR of 9.81% during the forecast period.

The global targeted protein degradation (TPD) market is experiencing steady and substantial growth. Targeted protein degradation focuses on developing therapies that selectively eliminate disease-causing proteins. Unlike traditional small-molecule inhibitors, TPD employs innovative mechanisms, such as PROTACs (Proteolysis Targeting Chimeras) and molecular glues, and other bifunctional molecules, to degrade unwanted proteins. This approach offers the potential to target previously undruggable proteins, thus broadening therapeutic options for conditions such as cancer, neurodegenerative diseases, and inflammatory disorders.

Moreover, the rising prevalence of cancer and increasing demand for adequate treatment are expected to boost the growth of the market. Additionally, increasing clinical studies and research activities are expected to contribute to the launch and commercialization of novel drugs, thereby driving market growth.

• For instance, in January 2025, AbbVie collaborated with Neomorph, Inc. to develop novel molecular glue degraders targeting multiple oncology and immunology

Key industry players, such as Arvinas and Kymera Therapeutics, operating in the market, are focusing on developing innovative products, advanced research and development, and strategic activities to maintain their market position.

TARGETED PROTEIN DEGRADATION MARKET TRENDS

Rising Research and Development Activities are a Key Market Trend

Research and development activities are driving the development and launch of novel pipeline candidates based on targeted protein degradation, a prominent global trend in the targeted protein degradation market. Many companies are investing heavily in discovering and optimizing novel degraders to expand their product pipelines. Additionally, pharmaceutical and biotech companies are focused on accelerating the progression from early-stage discovery to clinical trials, aiming to offer novel therapeutic targets and enhance drug specificity and efficacy, thereby shaping the targeted protein degradation market growth.

• For instance, in January 2026, Ascentage Pharma Group International announced the IND Clearance for the next-generation BTK-targeted protein degrader, APG-3288, from the U.S. Food and Drug Administration (FDA). This approval enables the initiation of clinical trials in patients with relapsed or refractory B-cell malignancies.

Download Free sample to learn more about this report.

MARKET DYNAMICS

MARKET DRIVERS

Rising Prevalence of Cancer to Drive Market Growth

The primary factor driving market growth is the increasing prevalence of cancer worldwide. Targeted protein degradation (TPD) is being explored and utilized in the treatment of various cancers, including breast cancer, lung cancer, prostate cancer, multiple myeloma, leukemia, ovarian cancer, and colorectal cancer. These drugs offer a novel approach by selectively degrading disease-causing proteins, providing potential treatments for resistant and hard-to-treat cancers, thus boosting product adoption and market growth.

• For instance, as per the U.S. Department of Health and Human Services, National Cancer Institute’s report, around 36,110 cases of multiple myeloma were reported in 2025 in the U.S.

MARKET RESTRAINTS

Off-Target Substrate Degradation to Limit Market Growth

Unintended degradation of proteins caused by TPD drugs presents a significant restraint to the market. These drugs can unintentionally trigger the destruction of proteins that are not intended targets, leading to the loss of vital proteins and increasing the risk of side effects. Additionally, this leads to limitations in maintaining the maximum safe dosage, thereby hampering the reduction of target proteins in patients. Thus, the concerns over accidental protein degradation lead to slow market growth and limit the widespread adoption of TPD-based therapies.

• For instance, in April 2025, Orum Therapeutics, Inc. discontinued clinical development of ORM-5029, a HER2-targeted GSPT1 degrader-antibody conjugate (DAC) due to an off-target substrate degradation issue.

MARKET OPPORTUNITIES

Approval of New Platforms to Present Several Market Growth Opportunities

The emergence of first-in-class approvals in new platforms within the TPD market signifies a transformative opportunity. These novel platforms, such as PROTACs and molecular glues, enable the selective degradation of disease-causing proteins, thus opening therapy for the untapped targets.

Additionally, many key companies are focusing on strategic activities, such as collaboration and obtaining approval for new platforms and drugs, to boost the growth of the global targeted protein degradation market.

• For instance, in August 2025, Arvinas, Inc. collaborated with Pfizer Inc. to announce that the U.S. Food and Drug Administration (FDA) had accepted their New Drug Application (NDA) for vepdegestrant. This medication is the first PROteolysis TArgeting Chimera (PROTAC) selective estrogen receptor degraders serds, for ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

MARKET CHALLENGES

High Cost and Manufacturing Complexities to Challenge Market Growth

The high cost associated with developing TPD therapies poses a significant barrier to market growth. These drugs require substantial investment in research, development, and manufacturing infrastructure. Additionally, manufacturing complexity further complicates commercialization, as producing TPD molecules often involves sophisticated techniques and stringent quality control measures.

Segmentation Analysis

By Degradation Platform

Molecular Glue Degraders Segment to Dominate due to their Ability Selectively and Efficiently Induce the Degradation of Disease-Related Proteins

Based on degradation platform, the market is categorized into molecular glue degraders, lysosome-targeted degraders, PROTACs, autophagy-targeted degraders, antibody-based targeted degraders, hydrophobic tagging-based degraders, and others.

The molecular glue degraders segment is expected to account for the largest share of the targeted protein degradation market. The molecular glue degraders segment held an 89.4% market share. The dominant share of the segment is driven by the ability of these platforms to selectively and efficiently induce the degradation of disease-related proteins. Additionally, increasing new activities to develop and commercialize products utilizing molecular glue degraders will help boost the segment’s growth.

• For instance, in June 2025, Gilead Sciences, Inc. and Kymera Therapeutics, Inc. entered into an exclusive license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) for the treatment of breast cancer and other solid tumors.

The PROTACs segment is expected to grow at a CAGR of 29.28% over the forecast period. 

To know how our report can help streamline your business, Speak to Analyst

By Drug

Proven Efficacy in Treating Hematological Cancers Boosted Lenalidomide Segment Dominance

Based on drug, the market is segmented into thalidomide, lenalidomide, fulvestrant, elacestrant, and others.

In 2025, the lenalidomide segment dominated the global market. The lenalidomide segment dominated the market, accounting for a 60.6% market share. The dominant share of the segment is driven by increasing demand for these drugs due to their proven efficacy in treating hematological cancers, which have established clinical benefits and widespread approval, contributing to the segment’s dominance. Additionally, new product launches of lenalidomide by key pharmaceutical companies are expected to boost the segment’s growth.

• For instance, in March 2022, Teva Pharmaceutical Industries Ltd announced the launch of the first generic version of Revlimid (lenalidomide capsules) in the U.S. in 5mg, 10mg, 15mg, and 25mg strengths.

The thalidomide segment is projected to grow at a CAGR of 11.31% over the forecast period. 

By Indication

Increasing Prevalence of Hematologic Malignancies to Lead the Segment’s Growth

Based on indication, the market is segmented into hematologic malignancies, solid tumors, and others.

The hematologic malignancies segment is anticipated to witness a dominant market share of 74.2% over the forecast period. The dominant share of the segment is due to the increasing prevalence of hematologic malignancies, such as multiple myeloma, leukemia, and the increasing demand for targeted treatment with improved efficacy and reduced resistance.

• For instance, according to the National Cancer Institute’s report, in 2025, an estimated 66,890 new leukemia cases were reported, which accounted for around 3.3% of total cancer cases.

 The solid tumors segment is projected to grow at a CAGR of 16.0% over the forecast period. 

By Route of Administration

Improved Patient Compliance and Generic Launch of Oral Drugs Boosted the Segment’s Growth

Based on route of administration, the market is segmented into oral and parenteral.

The oral segment held a dominant market share of 87.9%. The growth of the segment is attributed to the convenience, improved patient compliance, and its preference over other delivery methods. Additionally, the launch of generic versions of the drug in oral dosage forms is expected to boost the segment’s growth in the market.

• For instance, in September 2022, Dr. Reddy’s Laboratories announced the U.S. launch of Lenalidomide Capsules, a therapeutic equivalent generic version of Revlimid (lenalidomide)

 The parenteral segment is projected to grow at a CAGR of 14.94% over the forecast period. 

By Distribution Channel

Patient Centric Approach and Convenience Boosted the Retail Pharmacy Segment’s Growth

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacy sector held a significant portion of the market, accounting for a 53.0% share of the total segment.  The dominant share of the segment is attributed to the availability and widespread access to the drugs. Additionally, these channels are convenient for patients seeking innovative therapies. Additionally, increasing strategic activities to expand their distribution networks and offering a patient-centric approach facilitates the adoption of these advanced treatments.

• For instance, in October 2024, Calian Group Ltd. collaborated with Walmart Canada to expand the retailer’s specialty pharmacy capabilities through licensing Calian’s custom-built digital health platform, Nexi.

The hospital pharmacy segment is projected to grow at a CAGR of 12.75% over the forecast period. 

Targeted Protein Degradation Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant targeted protein degradation market share in 2024, valued at USD 3.01 billion, and maintained its leading position in 2025, with a value of USD 3.10 billion. The market in North America is expected to grow due to the rising prevalence of cancer, the presence of advanced research and development facilities, and the presence of key market players in the region.

U.S. Targeted Protein Degradation Market

Based on North America’s substantial contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 2.86 billion in 2025, accounting for roughly 48.1% of global targeted protein degradation sales.

Europe

Europe is projected to record a growth rate of 9.38% in the coming years and reach a valuation of USD 1.63 billion in 2025. The region’s growth in the market is driven by the rising prevalence and increasing demand for targeted treatment. Additionally, increasing investment in research and clinical studies is expected to boost the region’s growth.

U.K. Targeted Protein Degradation Market

The U.K.’s market in 2025 is estimated to be around USD 0.31 billion, representing approximately 5.3% of global revenues.

Germany Targeted Protein Degradation Market

Germany’s market is projected to reach approximately USD 0.37 billion in 2025, equivalent to around 6.3% of the global sales.

Asia Pacific

Asia Pacific is estimated to reach USD 0.89 billion in 2025 and secure the position of the third-largest region in the market. In the region, India and China are both estimated to reach USD 0.19 billion and USD 0.31 billion, respectively, in 2025. The rising demand for adequate treatment, combined with the presence of generic manufacturers offering effective generic drugs for TPD, is expected to boost the region’s growth.

Japan Targeted Protein Degradation Market

The market in Japan in 2025 is estimated to be around USD 0.15 billion, accounting for roughly 3.2% of the global revenues.

China Targeted Protein Degradation Market

China’s market is projected to be one of the largest worldwide, with 2025 revenues estimated at around USD 0.31 billion, representing roughly 5.3% of global sales.

India Targeted Protein Degradation Market

The Indian market in 2025 is estimated to be around USD 0.19 billion, accounting for roughly 3.2% of the global revenues.

Latin America and the Middle East & Africa

The Latin America and Middle East & Africa regions are expected to witness moderate growth in this market during the forecast period. The Latin American market is set to reach a valuation of USD 0.17 billion in 2025. The rising prevalence of cancer and increasing demand for targeted treatment are expected to drive the region’s growth. In the Middle East & Africa, the GCC is set to reach a value of USD 0.07 billion in 2025.

COMPETITIVE LANDSCAPE

Key Industry Players

Emphasis on Key Players to Offer Adequate Facility Management Services for Healthcare Systems

The global targeted protein degradation market has a highly consolidated structure, with several established large pharma partners that provide development scale and commercialization reach.

Arvinas and Kymera Therapeutics Inc. hold prominent positions with their clinically advanced degrader portfolios and strategic partners, accelerating late-stage development and market access.

Other notable players, such as Pfizer Inc., Sanofi, and Bristol Myers Squibb, along with others that have strengthened leadership and deep oncology portfolios, are expanding their degraders pipelines and strengthening their market position.

LIST OF KEY TARGETED PROTEIN DEGRADATION COMPANIES PROFILED

• Arvinas (U.S.)
• Kymera Therapeutics, Inc. (U.S.)
• C4 Therapeutics (U.S.)
• Nurix Therapeutics (U.S.)
• Monte Rosa Therapeutics (U.S.)
• Captor Therapeutics, Poland
• Pfizer, Inc. (U.S.)
• Bristol Myers Squibb (U.S.)
• Novartis (Switzerland)
• Sanofi (France)

KEY INDUSTRY DEVELOPMENTS

• January 2026: Kymera Therapeutics, Inc. announced the advancement of a new class of oral small-molecule degrader medicines, KT-621, for immunological diseases.
• April 2025: Evotec SE, in collaboration with Bristol Myers Squibb, announced progress in the molecular glue-based pipeline for addressing unmet medical needs.
• March 2025: Nurix Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to bexobrutideg (NX-5948) for the treatment of Waldenström macroglobulinemia (WM).
• December 2024: Monte Rosa Therapeutics, Inc. announced the update on the ongoing Phase 1/2 open-label study of MRT-2359 in patients with MYC-driven solid tumors.
• April 2024: Nurix Therapeutics, Inc. announced the extension of the ongoing research program with Sanofi for STAT6 (signal transducer and activator of transcription 6) for type 2 inflammation.

REPORT COVERAGE

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation